Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Treatment of antibody-mediated post-transplant autoimmune-like pepatitis with daratumumab

Akshay Sharma • 2 Feb 2021
TCT 2021
Acute Lymphoblastic Leukemia Leukemia Antibodies Daratumumab

Akshay Sharma, MBBS, St. Jude Children’s Research Hospital, Memphis, TN, presents a case study of the use of daratumumab, an anti-CD38 monoclonal antibody, for post-transplant autoimmune-like hepatitis in a patient with B-cell acute lymphoblastic leukemia who underwent hematopoietic cell transplantation. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Akshay Sharma

The risk of developing leukemia after lentiviral gene therapy
5:44
The risk of developing leukemia after lentiviral gene therapy
Akshay Sharma • 9 Apr 2025
The role of palliative care in patients with sickle cell disease undergoing SCT or gene therapy
1:58
The role of palliative care in patients with sickle cell disease undergoing SCT or gene therapy
Akshay Sharma • 9 Apr 2025
The main benefits and challenges of gene therapy for sickle cell disease
4:08
The main benefits and challenges of gene therapy for sickle cell disease
Akshay Sharma • 9 Apr 2025
Is there a risk of infection and a need for re-vaccination after gene therapy?
3:23
Is there a risk of infection and a need for re-vaccination after gene therapy?
Akshay Sharma • 9 Apr 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals